<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01220024</url>
  </required_header>
  <id_info>
    <org_study_id>INN-CB-010</org_study_id>
    <nct_id>NCT01220024</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of CollaRx® Bupivacaine Implant in Men After Open Laparotomy Herniorrhaphy</brief_title>
  <official_title>A Phase II, Randomized, Single Dose, Double-blind, Placebo Controlled Study to Investigate the Efficacy and Safety Profile of the CollaRx® Bupivacaine Implant (200 mg Bupivacaine Hydrochloride) in Men After Open Laparotomy Herniorrhaphy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innocoll</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Premier Research Group plc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Innocoll</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess pain intensity for the first 72 hrs after after aggravated movement&#xD;
      (cough)following open laparotomy inguinal herniorrhaphy in patient who receive either the&#xD;
      CollaRx Bupivacaine implant or a plain collagen sponge.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inguinal herniorrhaphy is a common surgery; and common surgical methods used include&#xD;
      laparoscopic and open placement of synthetic mesh. The use of synthetic mesh can greatly&#xD;
      reduce the risk of hernia recurrence regardless of the method used for its placement.&#xD;
      Managing postoperative pain and preventing morbidity after open mesh herniorrhaphy remain&#xD;
      considerable medical challenges.&#xD;
&#xD;
      Bupivacaine is a local anesthetic (pain medicine) that has an established safety profile.&#xD;
      Collagen is a protein that is found in all mammals. The CollaRx Bupivacaine implant is a thin&#xD;
      flat sponge made out of collagen that comes from cow tendons and contains bupivacaine. When&#xD;
      inserted into a surgical site, the collagen breaks down and bupivacaine is released at the&#xD;
      site but very little is absorbed into the blood stream. The high levels of bupivacaine at the&#xD;
      surgical site may result in less pain for several days after surgery.&#xD;
&#xD;
      This study will assess pain intensity after surgery in patients who receive either the&#xD;
      CollaRx Bupivacaine implant or a plain collagen sponge.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2, 2010</start_date>
  <completion_date type="Actual">May 18, 2011</completion_date>
  <primary_completion_date type="Actual">May 18, 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sum of Pain Intensity Defined as Area Under the Curve (AUC) of 100-mm VAS PI Scores.</measure>
    <time_frame>1, 2, 4, 6, 8, 10, 12, 24, 48, and 72 hours.</time_frame>
    <description>The primary efficacy variable was SPI defined as area under the curve (AUC) of 100-mm VAS pain intensity scores after aggravated movement (cough) from 1 to 72 hours after surgery. Minimum score is &quot;0&quot;. Maximum score is 7200. This represents the AUC (Area Under the Curve) of the pain intensities when calculated with the trapezoidal rule. A lower score means a better outcome or less pain reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sum of Pain Intensity (SPI) After Aggravated Movement (Cough)</measure>
    <time_frame>1, 2, 4, 6, 8, 10, 12, 24, 48, and 72 hours.</time_frame>
    <description>Measured on a Visual Analog Pain Scale (VAS) with the lowest possible value of 0 and highest 100 (0 - 100) at each time point. A lower score is better which means the patient experience lower pain. The score is calculated using the number of hours * the VAS score. This represents the AUC (Area Under the Curve) of the pain intensities when calculated with the trapezoidal rule. For each measure outcome - the minimum score is &quot;0&quot; and the maximum score is 100* the number of hours in that period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sum of Pain Intensity (SPI) Using a Visual Analog Scale (VAS) When at Rest</measure>
    <time_frame>1, 2, 4, 6, 8, 10, 12, 24, 48, and 72 hours.</time_frame>
    <description>Measured on a Visual Analog Pain Scale (VAS) with the lowest possible value of 0 and highest 100 (0 - 100) at each time point. A lower score is better which means the patient experience lower pain. The score is calculated using the number of hours * the VAS score. This represents the AUC (Area Under the Curve) of the pain intensities when calculated with the trapezoidal rule. For each measure outcome - the minimum score is &quot;0&quot; and the maximum score is 100* the number of hours in that period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Intensity Visual Analog Pain Scale Scores Over Time After Aggravated Movement (Cough)</measure>
    <time_frame>1,2,4,6,8,10,12,24,48 and 72 hours</time_frame>
    <description>Measured on a Visual Analog Pain Scale (VAS) with the lowest possible value of 0 and highest 100 (0 - 100). Patients were asked during multiple time points to provide a score on this VAS scale. The lower the sore the better the outcome. Higher score is a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Intensity VAS Scores Over Time at Rest</measure>
    <time_frame>1,2,4,6,8,10,12,24,48 and 72 hours</time_frame>
    <description>Measured on a Visual Analog Pain Scale (VAS) with the lowest possible value of 0 and highest 100 (0 - 100). Patients were asked during multiple time points to provide a score on this VAS scale. Lower score is better. Higher score means more pain. Time points are summarized independently</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Sum of Pain Intensity (SPI) Categorical Scores After Aggravated Movement</measure>
    <time_frame>1,2,4,6,8,10,12,24,48 and 72 hours</time_frame>
    <description>Measured on a Visual Analog Pain Scale (VAS) with the lowest possible value of 0 and highest 100 (0 - 100) for each timepoint. (timepoints 1,2,4,6,8,10,12,24,48 and 72 hours ) Patients were asked during multiple time points to provide a score on this VAS scale. For 1 to 24 hours the highest score possible would be 800. For 1 to 48 hours the highest score possible would be 900. For 1 to 72 hours the highest score possible would be 1000. A mean Lower score is better. A mean Higher score is a worse outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Herniorrhaphy</condition>
  <condition>Postoperative Pain</condition>
  <condition>Inguinal Hernia</condition>
  <arm_group>
    <arm_group_label>2, 5x5cm bupivacaine collagen sponges</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>collagen sponges</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2, Placebo collagen sponges</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo collagen sponges</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine Collagen Sponge</intervention_name>
    <description>Drug: Bupivacaine Collagen Sponge</description>
    <arm_group_label>2, 5x5cm bupivacaine collagen sponges</arm_group_label>
    <other_name>Bupivacaine Implant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo collagen Sponge</intervention_name>
    <description>Drug: Placebo Collagen Sponge</description>
    <arm_group_label>2, Placebo collagen sponges</arm_group_label>
    <other_name>Collagen Implant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Man ≥ 18 years&#xD;
&#xD;
          -  Body mass index (BMI) ≥ 19 and ≤ 40 kg/m2.&#xD;
&#xD;
          -  Has a planned unilateral inguinal herniorrhaphy (open laparotomy, tension free&#xD;
             technique) to be performed according to standard surgical technique under general&#xD;
             anesthesia.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has a known hypersensitivity to amide local anesthetics, opioids, or bovine products.&#xD;
&#xD;
          -  Scheduled for bilateral inguinal herniorrhaphy.&#xD;
&#xD;
          -  Undergone a prior herniorrhaphy on the side scheduled for repair.&#xD;
&#xD;
          -  Undergone major surgery within 3 mos of the scheduled herniorrhaphy.&#xD;
&#xD;
          -  Has cardiac arrhythmias or atrioventricular (AV) conduction disorders.&#xD;
&#xD;
          -  Concomitantly uses antiarrhythmics (eg, amiodarone, lidocaine), propranolol, or&#xD;
             strong/moderate cytochrome P450 (CYP) 3A4 inhibitors or inducers (eg, macrolide&#xD;
             antibiotics and grapefruit juice).&#xD;
&#xD;
          -  Used long acting analgesics within 24 hours of surgery. Short acting analgesics such&#xD;
             as acetaminophen may be used on the day of surgery but are subject to preoperative&#xD;
             restrictions for oral intake.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Prior</last_name>
    <role>Study Director</role>
    <affiliation>Innocoll</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Cusack SL, Jaros M, Kuss M, Minkowitz HS, Winkle P, Hemsen L. Clinical evaluation of XaraColl(®), a bupivacaine-collagen implant, for postoperative analgesia in two multicenter, randomized, double-blind, placebo-controlled pilot studies. J Pain Res. 2012;5:217-25. doi: 10.2147/JPR.S33453. Epub 2012 Jun 27.</citation>
    <PMID>22792007</PMID>
  </results_reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>September 23, 2010</study_first_submitted>
  <study_first_submitted_qc>October 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2010</study_first_posted>
  <results_first_submitted>September 25, 2020</results_first_submitted>
  <results_first_submitted_qc>February 18, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 10, 2021</results_first_posted>
  <last_update_submitted>February 18, 2021</last_update_submitted>
  <last_update_submitted_qc>February 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hernia, Inguinal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>medical investigative sites</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>2, 5x5cm Bupivacaine Collagen Sponges</title>
          <description>Bupivacaine Collagen Sponge: Drug: Bupivacaine Collagen Sponge - Two 5 × 5-cm bupivacaine sponges each containing 75 mg of Type I collagen and 100 mg bupivacaine hydrochloride,</description>
        </group>
        <group group_id="P2">
          <title>2, Placebo Collagen Sponges</title>
          <description>Placebo collagen Sponge: Drug: Placebo Collagen Sponge - Two 5 × 5-cm placebo sponges each containing 75 mg of Type I collagen.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Randomized subjects</population>
      <group_list>
        <group group_id="B1">
          <title>2, 5x5cm Bupivacaine Collagen Sponges</title>
          <description>Bupivacaine Collagen Sponge: Drug: Bupivacaine Collagen Sponge</description>
        </group>
        <group group_id="B2">
          <title>2, Placebo Collagen Sponges</title>
          <description>Placebo collagen Sponge: Drug: Placebo Collagen Sponge</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.8" spread="12.3"/>
                    <measurement group_id="B2" value="41.7" spread="14.9"/>
                    <measurement group_id="B3" value="44.7" spread="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sum of Pain Intensity Defined as Area Under the Curve (AUC) of 100-mm VAS PI Scores.</title>
        <description>The primary efficacy variable was SPI defined as area under the curve (AUC) of 100-mm VAS pain intensity scores after aggravated movement (cough) from 1 to 72 hours after surgery. Minimum score is &quot;0&quot;. Maximum score is 7200. This represents the AUC (Area Under the Curve) of the pain intensities when calculated with the trapezoidal rule. A lower score means a better outcome or less pain reported.</description>
        <time_frame>1, 2, 4, 6, 8, 10, 12, 24, 48, and 72 hours.</time_frame>
        <population>Intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>2, 5x5cm Bupivacaine Collagen Sponges</title>
            <description>Bupivacaine Collagen Sponge: Drug: Bupivacaine Collagen Sponge</description>
          </group>
          <group group_id="O2">
            <title>2, Placebo Collagen Sponges</title>
            <description>Placebo collagen Sponge: Drug: Placebo Collagen Sponge</description>
          </group>
        </group_list>
        <measure>
          <title>Sum of Pain Intensity Defined as Area Under the Curve (AUC) of 100-mm VAS PI Scores.</title>
          <description>The primary efficacy variable was SPI defined as area under the curve (AUC) of 100-mm VAS pain intensity scores after aggravated movement (cough) from 1 to 72 hours after surgery. Minimum score is &quot;0&quot;. Maximum score is 7200. This represents the AUC (Area Under the Curve) of the pain intensities when calculated with the trapezoidal rule. A lower score means a better outcome or less pain reported.</description>
          <population>Intent-to-treat population</population>
          <units>score on a scale*hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2810.4" spread="1693.43"/>
                    <measurement group_id="O2" value="3484.5" spread="1806.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sum of Pain Intensity (SPI) After Aggravated Movement (Cough)</title>
        <description>Measured on a Visual Analog Pain Scale (VAS) with the lowest possible value of 0 and highest 100 (0 - 100) at each time point. A lower score is better which means the patient experience lower pain. The score is calculated using the number of hours * the VAS score. This represents the AUC (Area Under the Curve) of the pain intensities when calculated with the trapezoidal rule. For each measure outcome - the minimum score is &quot;0&quot; and the maximum score is 100* the number of hours in that period.</description>
        <time_frame>1, 2, 4, 6, 8, 10, 12, 24, 48, and 72 hours.</time_frame>
        <population>Intent-to-Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>2, 5x5cm Bupivacaine Collagen Sponges</title>
            <description>Bupivacaine Collagen Sponge: Drug: Bupivacaine Collagen Sponge</description>
          </group>
          <group group_id="O2">
            <title>2, Placebo Collagen Sponges</title>
            <description>Placebo collagen Sponge: Drug: Placebo Collagen Sponge</description>
          </group>
        </group_list>
        <measure>
          <title>Sum of Pain Intensity (SPI) After Aggravated Movement (Cough)</title>
          <description>Measured on a Visual Analog Pain Scale (VAS) with the lowest possible value of 0 and highest 100 (0 - 100) at each time point. A lower score is better which means the patient experience lower pain. The score is calculated using the number of hours * the VAS score. This represents the AUC (Area Under the Curve) of the pain intensities when calculated with the trapezoidal rule. For each measure outcome - the minimum score is &quot;0&quot; and the maximum score is 100* the number of hours in that period.</description>
          <population>Intent-to-Treat Population</population>
          <units>score on a scale*hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 to 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="996.3" spread="503.65"/>
                    <measurement group_id="O2" value="1270.4" spread="566.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25 to 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1021.8" spread="604.71"/>
                    <measurement group_id="O2" value="1186.7" spread="647.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 to 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2018.2" spread="1092.85"/>
                    <measurement group_id="O2" value="2457.2" spread="1155.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>49 to 72 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="792.2" spread="633.88"/>
                    <measurement group_id="O2" value="1027.4" spread="713.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sum of Pain Intensity (SPI) Using a Visual Analog Scale (VAS) When at Rest</title>
        <description>Measured on a Visual Analog Pain Scale (VAS) with the lowest possible value of 0 and highest 100 (0 - 100) at each time point. A lower score is better which means the patient experience lower pain. The score is calculated using the number of hours * the VAS score. This represents the AUC (Area Under the Curve) of the pain intensities when calculated with the trapezoidal rule. For each measure outcome - the minimum score is &quot;0&quot; and the maximum score is 100* the number of hours in that period.</description>
        <time_frame>1, 2, 4, 6, 8, 10, 12, 24, 48, and 72 hours.</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>2, 5x5cm Bupivacaine Collagen Sponges</title>
            <description>Bupivacaine Collagen Sponge: Drug: Bupivacaine Collagen Sponge</description>
          </group>
          <group group_id="O2">
            <title>2, Placebo Collagen Sponges</title>
            <description>Placebo collagen Sponge: Drug: Placebo Collagen Sponge</description>
          </group>
        </group_list>
        <measure>
          <title>Sum of Pain Intensity (SPI) Using a Visual Analog Scale (VAS) When at Rest</title>
          <description>Measured on a Visual Analog Pain Scale (VAS) with the lowest possible value of 0 and highest 100 (0 - 100) at each time point. A lower score is better which means the patient experience lower pain. The score is calculated using the number of hours * the VAS score. This represents the AUC (Area Under the Curve) of the pain intensities when calculated with the trapezoidal rule. For each measure outcome - the minimum score is &quot;0&quot; and the maximum score is 100* the number of hours in that period.</description>
          <population>ITT population</population>
          <units>score on a scale*hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 to 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="741.6" spread="452.29"/>
                    <measurement group_id="O2" value="856.6" spread="486.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25 to 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="754.7" spread="538.41"/>
                    <measurement group_id="O2" value="677.2" spread="455.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 to 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1496.4" spread="978.74"/>
                    <measurement group_id="O2" value="1533.8" spread="875.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>49 to 72 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="567.0" spread="565.64"/>
                    <measurement group_id="O2" value="501.3" spread="451.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 to 72 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2063.4" spread="1511.89"/>
                    <measurement group_id="O2" value="2035.0" spread="1271.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Intensity Visual Analog Pain Scale Scores Over Time After Aggravated Movement (Cough)</title>
        <description>Measured on a Visual Analog Pain Scale (VAS) with the lowest possible value of 0 and highest 100 (0 - 100). Patients were asked during multiple time points to provide a score on this VAS scale. The lower the sore the better the outcome. Higher score is a worse outcome</description>
        <time_frame>1,2,4,6,8,10,12,24,48 and 72 hours</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>2, 5x5cm Bupivacaine Collagen Sponges</title>
            <description>Bupivacaine Collagen Sponge: Drug: Bupivacaine Collagen Sponge</description>
          </group>
          <group group_id="O2">
            <title>2, Placebo Collagen Sponges</title>
            <description>Placebo collagen Sponge: Drug: Placebo Collagen Sponge</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Intensity Visual Analog Pain Scale Scores Over Time After Aggravated Movement (Cough)</title>
          <description>Measured on a Visual Analog Pain Scale (VAS) with the lowest possible value of 0 and highest 100 (0 - 100). Patients were asked during multiple time points to provide a score on this VAS scale. The lower the sore the better the outcome. Higher score is a worse outcome</description>
          <population>ITT Population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hour 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.4" spread="28.59"/>
                    <measurement group_id="O2" value="73.4" spread="22.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.6" spread="24.88"/>
                    <measurement group_id="O2" value="60.6" spread="22.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.2" spread="26.10"/>
                    <measurement group_id="O2" value="57.0" spread="24.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.2" spread="24.95"/>
                    <measurement group_id="O2" value="58.8" spread="26.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.0" spread="24.83"/>
                    <measurement group_id="O2" value="54.3" spread="27.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.4" spread="25.54"/>
                    <measurement group_id="O2" value="52.0" spread="30.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.7" spread="28.18"/>
                    <measurement group_id="O2" value="28.18" spread="29.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.2" spread="26.37"/>
                    <measurement group_id="O2" value="51.5" spread="26.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.0" spread="27.31"/>
                    <measurement group_id="O2" value="47.2" spread="29.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.8" spread="27.00"/>
                    <measurement group_id="O2" value="38.3" spread="30.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Intensity VAS Scores Over Time at Rest</title>
        <description>Measured on a Visual Analog Pain Scale (VAS) with the lowest possible value of 0 and highest 100 (0 - 100). Patients were asked during multiple time points to provide a score on this VAS scale. Lower score is better. Higher score means more pain. Time points are summarized independently</description>
        <time_frame>1,2,4,6,8,10,12,24,48 and 72 hours</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>2, 5x5cm Bupivacaine Collagen Sponges</title>
            <description>Bupivacaine Collagen Sponge: Drug: Bupivacaine Collagen Sponge</description>
          </group>
          <group group_id="O2">
            <title>2, Placebo Collagen Sponges</title>
            <description>Placebo collagen Sponge: Drug: Placebo Collagen Sponge</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Intensity VAS Scores Over Time at Rest</title>
          <description>Measured on a Visual Analog Pain Scale (VAS) with the lowest possible value of 0 and highest 100 (0 - 100). Patients were asked during multiple time points to provide a score on this VAS scale. Lower score is better. Higher score means more pain. Time points are summarized independently</description>
          <population>ITT population</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hour 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.6" spread="29.20"/>
                    <measurement group_id="O2" value="73.4" spread="22.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.2" spread="25.20"/>
                    <measurement group_id="O2" value="60.6" spread="22.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.6" spread="24.60"/>
                    <measurement group_id="O2" value="57.0" spread="24.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.5" spread="25.45"/>
                    <measurement group_id="O2" value="58.8" spread="26.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.3" spread="25.33"/>
                    <measurement group_id="O2" value="54.3" spread="27.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.0" spread="25.93"/>
                    <measurement group_id="O2" value="52.0" spread="30.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.6" spread="28.47"/>
                    <measurement group_id="O2" value="55.2" spread="29.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.3" spread="26.92"/>
                    <measurement group_id="O2" value="51.5" spread="26.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.3" spread="27.85"/>
                    <measurement group_id="O2" value="47.2" spread="29.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.7" spread="27.23"/>
                    <measurement group_id="O2" value="38.3" spread="30.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Sum of Pain Intensity (SPI) Categorical Scores After Aggravated Movement</title>
        <description>Measured on a Visual Analog Pain Scale (VAS) with the lowest possible value of 0 and highest 100 (0 - 100) for each timepoint. (timepoints 1,2,4,6,8,10,12,24,48 and 72 hours ) Patients were asked during multiple time points to provide a score on this VAS scale. For 1 to 24 hours the highest score possible would be 800. For 1 to 48 hours the highest score possible would be 900. For 1 to 72 hours the highest score possible would be 1000. A mean Lower score is better. A mean Higher score is a worse outcome.</description>
        <time_frame>1,2,4,6,8,10,12,24,48 and 72 hours</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>2, 5x5cm Bupivacaine Collagen Sponges</title>
            <description>Bupivacaine Collagen Sponge: Drug: Bupivacaine Collagen Sponge</description>
          </group>
          <group group_id="O2">
            <title>2, Placebo Collagen Sponges</title>
            <description>Placebo collagen Sponge: Drug: Placebo Collagen Sponge</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Sum of Pain Intensity (SPI) Categorical Scores After Aggravated Movement</title>
          <description>Measured on a Visual Analog Pain Scale (VAS) with the lowest possible value of 0 and highest 100 (0 - 100) for each timepoint. (timepoints 1,2,4,6,8,10,12,24,48 and 72 hours ) Patients were asked during multiple time points to provide a score on this VAS scale. For 1 to 24 hours the highest score possible would be 800. For 1 to 48 hours the highest score possible would be 900. For 1 to 72 hours the highest score possible would be 1000. A mean Lower score is better. A mean Higher score is a worse outcome.</description>
          <population>ITT population</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 to 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.6" spread="13.64"/>
                    <measurement group_id="O2" value="45.6" spread="13.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 to 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3" spread="29.63"/>
                    <measurement group_id="O2" value="90.2" spread="27.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 to 72 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118.9" spread="44.80"/>
                    <measurement group_id="O2" value="128.8" spread="46.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>2, 5x5cm Bupivacaine Collagen Sponges</title>
          <description>Bupivacaine Collagen Sponge: Drug: Bupivacaine Collagen Sponge</description>
        </group>
        <group group_id="E2">
          <title>2, Placebo Collagen Sponges</title>
          <description>Placebo collagen Sponge: Drug: Placebo Collagen Sponge</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Incision site infection</sub_title>
                <description>both were mild</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Scrotal swelling</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Charlene A. Tucker, MS Executive Director, Medical Writing and Document Management</name_or_title>
      <organization>Innocoll</organization>
      <phone>484-406-5211</phone>
      <email>ctucker@innocoll.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

